Abstract

BackgroundStructured Product Labeling (SPL) is a document markup standard approved by Health Level Seven (HL7) and adopted by United States Food and Drug Administration (FDA) as a mechanism for exchanging drug product information. The SPL drug labels contain rich information about FDA approved clinical drugs. However, the lack of linkage to standard drug ontologies hinders their meaningful use. NDF-RT (National Drug File Reference Terminology) and NLM RxNorm as standard drug ontology were used to standardize and profile the product labels.MethodsIn this paper, we present a framework that intends to map SPL drug labels with existing drug ontologies: NDF-RT and RxNorm. We also applied existing categorical annotations from the drug ontologies to classify SPL drug labels into corresponding classes. We established the classification and relevant linkage for SPL drug labels using the following three approaches. First, we retrieved NDF-RT categorical information from the External Pharmacologic Class (EPC) indexing SPLs. Second, we used the RxNorm and NDF-RT mappings to classify and link SPLs with NDF-RT categories. Third, we profiled SPLs using RxNorm term type information. In the implementation process, we employed a Semantic Web technology framework, in which we stored the data sets from NDF-RT and SPLs into a RDF triple store, and executed SPARQL queries to retrieve data from customized SPARQL endpoints. Meanwhile, we imported RxNorm data into MySQL relational database.ResultsIn total, 96.0% SPL drug labels were mapped with NDF-RT categories whereas 97.0% SPL drug labels are linked to RxNorm codes. We found that the majority of SPL drug labels are mapped to chemical ingredient concepts in both drug ontologies whereas a relatively small portion of SPL drug labels are mapped to clinical drug concepts.ConclusionsThe profiling outcomes produced by this study would provide useful insights on meaningful use of FDA SPL drug labels in clinical applications through standard drug ontologies such as NDF-RT and RxNorm.

Highlights

  • Structured Product Labeling (SPL) [1] encodes very rich clinical drug knowledge, such as dosage, strength, usage of drug, etc

  • We have successfully mapped SPL labels to National Drug File Reference Terminology (NDF-RT) and RxNorm, and categorized them using drug class information and clinical drug identification information respectively. 96.0% of SPL drug labels are mapped with NDF-RT categories whereas 97.0% of SPL drug labels are linked to RxNorm codes

  • We found that the majority of SPL drug labels are mapped to chemical ingredient concepts in both drug ontologies whereas a relatively small portion of SPL drug labels are mapped to clinical drug concepts

Read more

Summary

Introduction

Structured Product Labeling (SPL) [1] encodes very rich clinical drug knowledge, such as dosage, strength, usage of drug, etc. The drug information/ knowledge written into SPL drug labels is currently in unstructured free text instead of structured codified information, which poses significant challenges to computational analysis of the knowledge, and hinders the integration of SPL drug labels with other existing knowledge bases. This is a common scenario occurring in the biomedical domain, where dozens of public resources involve laborious processes to manually annotate data. Structured Product Labeling (SPL) is a document markup standard approved by Health Level Seven (HL7) and adopted by United States Food and Drug Administration (FDA) as a mechanism for exchanging drug product information. Three kinds of drug concepts are involved in this study, “VA Product”, “Chemical Ingredient” and “EPC”, of which “VA Product”, and “Chemical Ingredient” are relevant to “Clinical Drug”, “Generic Ingredient or Combination” and “EPC” is analogous with the “VA Drug Classification” respectively

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.